Therefore, unwanted CD33-specific “on target” toxicities toward these cells must be expected with the use of potent CD33-targeted therapies, manifesting primarily as prolonged myelosuppression and associated risks of infections and/or bleeding. This evidence concerns the gene CD33 and infection.